Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?Francesca Daniel, Antonio Frassoldati, M. Fabbri et al.|Annals of Oncology|2016Cited by 1
The regorafenib issue: focus on efficacy and safety in pre-treated metastatic colorectal cancer from a real world experienceFrancesca Daniel, Antonio Frassoldati, E. Bannò et al.|Annals of Oncology|2017Cited by 1
Estrogen receptor mutation: a new strategy to overcome endocrine resistanceAndrea Moretti, Antonio Frassoldati, F. Daniel et al.|Annals of Oncology|2017Cited by 1